Alaunos Therapeutics

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOUSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Alaunos expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares of the common stock sold in the public offering. All of the securities in the offering are to be sold by Alaunos. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

First-in-human data from two patients using TCR-T cell therapy produced, at best, one partial response. While not targeting solid tumors, approved CAR-T cell therapies do demonstrate high complete response rates.

Alaunos Therapeutics Still Waiting For Home Run

Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle Senior - Chief Executive Officer Abhi Srivastava - Vice President, Technical Operations Drew Deniger - Vice President, Research and Development Mike Wong - Vice President, Finance Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald James Shin - Wells Fargo Yale Jen - Laidlaw Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Alaunos Therapeutics Third Quarter 2022 Financial Results Conference Call.

Alaunos Therapeutics, Inc. (TCRT) Q3 2022 Earnings Call Transcript

HOUSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the third quarter ended September 30, 2022.

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting the potential of the Company's human neoantigen T-cell receptor platform (hunTR) to expand its TCR Library. The data will be presented at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting in Boston, Massachusetts from November 8-12, 2022.

Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Pulse Biosciences

Spero Therapeutics

Hot penny stocks to add to your watch list this week. Is it time to buy?

Hot Penny Stocks To Watch As The Stock Market Crash Continues

HOUSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced early clinical data from the first patient in its ongoing TCR-T Library Phase 1/2 trial. The data will be presented during a proffered talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) being held in New York, NY from September 28 through October 1, 2022.

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

Four of the biotech's top managers reveal they've exercised stock options, and investors are following suit by snapping up shares.

Why Alaunos Therapeutics Triumphed On Tuesday

AMTD International Inc

Banco Bradesco

Quoin Pharmaceuticals Ltd

Hot penny stocks to watch today. The post Hot Penny Stocks To Watch Today As Stock Market Crash Continues appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Watch Today As Stock Market Crash Continues

Bright Minds Biosciences

Gevo

How to make money with penny stocks during a market crash The post Making Money With Penny Stocks When the Market Crashes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Making Money With Penny Stocks When the Market Crashes

Appian

These 2 Stocks Stood Strong Despite the Nasdaq's Friday Fall

The biotech is rebounding after yesterday's big sell-off.

Why Alaunos Therapeutics Stock Is Soaring Today

Applied Optoelectronics

India Globalization Capital

Penny stocks to buy? High volume has placed them on the watch list in the stock market today.

4 High Volume Penny Stocks To Watch While The Stock Market Is Down

100% technical buy signals. 10 new highs and up 105.45% in the last month.

Alaunos Therapeutics - T-Cell Therapies

Investors appeared to take profits off the table after the biotech's positive news last week.

Why Alaunos Therapeutics Stock Sank Today

HOUSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will be participating in the following upcoming investor conferences.

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September

A specialty cancer therapy developed by the company shows some rather promising results.

Why Alaunos Therapeutics Topped the Market on Tuesday

Agile Therapeutics

Baudax Bio

Clarus Therapeutics Holdings

Nine Energy Service

Quanergy Systems

Revelation Biosciences

Trevi Therapeutics Inc

Mammoth Energy Services

Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).

These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)

Shorts appear to be moving to the sidelines ahead of an upcoming presentation.

Why Alaunos Therapeutics Stock Is Up Yet Again Today

Alaunos results from a phase 1/2 study using TCR-Ts to treat 6 solid tumor types with hotspot mutations are expected in Q3 of 2022. Non-viral Sleeping Beauty is what makes it possible for Alaunos to genetically modify T-Cell receptors to target neoantigens on tumors.

Alaunos: Taking Autologous T-Cell Receptor Therapies To The Next Step

The biotech's stock is giving back some of its recent gains.

Why Alaunos Therapeutics Stock Is Tumbling Today

Biofrontera

Yatsen Holding

Penny stocks to watch with relative strength in the stock market today. The post Best Penny Stocks To Watch After Powell's Jackson Hole Speech appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Alaunos Therapeutics Stock (TCRT)